| Title |
Management of scalp psoriasis: current perspectives
|
|---|---|
| Published in |
Psoriasis : Targets and Therapy, March 2016
|
| DOI | 10.2147/ptt.s85330 |
| Pubmed ID | |
| Authors |
Kim Blakely, Melinda Gooderham |
| Abstract |
Psoriasis is a chronic inflammatory condition. The age of onset, chronicity, physical, and psychosocial consequences of the disease cause psoriasis to have a significant impact on patient quality of life. Scalp psoriasis is no different, and effective treatment results in an improvement in quality of life. Successful management of scalp psoriasis includes topical therapies that are acceptable to the patient for mild-to-moderate disease, and systemic therapies for recalcitrant or moderate-to-severe disease. The most effective topical therapies are corticosteroid products, or combination products with calcipotriol and corticosteroid. Newer vehicle options provide more attractive and pleasing products for patients and may improve adherence. The current perspectives for management of scalp psoriasis are discussed including available data for systemic therapy of severe disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 13% |
| Student > Ph. D. Student | 6 | 11% |
| Other | 5 | 9% |
| Researcher | 5 | 9% |
| Student > Postgraduate | 4 | 8% |
| Other | 7 | 13% |
| Unknown | 19 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Chemistry | 3 | 6% |
| Environmental Science | 1 | 2% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 20 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 491. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2023.
All research outputs
#53,502
of 25,457,858 outputs
Outputs from Psoriasis : Targets and Therapy
#2
of 88 outputs
Outputs of similar age
#934
of 312,788 outputs
Outputs of similar age from Psoriasis : Targets and Therapy
#1
of 2 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 88 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,788 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them